Phase 3 study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine

Tripathy, D, Tolaney, S, Seidman, AD et al. (5 more authors) (2017) Phase 3 study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine. In: Cancer Research. 2016 San Antonio Breast Cancer Symposium, 06 Dec 2016 - 10 Dec 2010, San Antonio, Texas, U.S.A.. American Association for Cancer Research .

Metadata

Authors/Creators:
  • Tripathy, D
  • Tolaney, S
  • Seidman, AD
  • Anders, CK
  • Ibrahim, N
  • Rugo, HS
  • Twelves, CJ
  • Cortes, J
Dates:
  • Published (online): 15 February 2017
  • Published: February 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 11 Jul 2019 13:59
Last Modified: 11 Jul 2019 15:01
Status: Published
Publisher: American Association for Cancer Research
Identification Number: https://doi.org/10.1158/1538-7445.SABCS16-OT1-04-08
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics